Dosimetry

Dosimetry shows how radiation spreads and is absorbed, guiding the safe and effective design of radioligand therapies prior to clinical practise.

Dosimetry analysis is essential in preclinical evaluation of radioligand therapies, as it quantifies radiation doses delivered to tissues and organs. Using in vivo imaging modalities such as small-animal PET or SPECT, medical scientists can monitor tracer kinetics and derive time-activity curves that form the basis for accurate absorbed dose estimates and radiobiological modelling.

Ex vivo biodistribution complements imaging by providing precise, tissue-level quantification of tracer uptake, validating and refining imaging-based dosimetry. Together, these methods ensure reliable dose assessments that enhance the translational relevance of preclinical data.

By integrating dosimetry with in vivo and ex vivo analyses, medical scientists can optimise activity administration, predict therapeutic response, and inform patient-specific planning. This approach accelerates safe clinical translation and supports evidence-based optimisation of radioligand therapy in practice.

Services include:

• Design and execution of experiments to determine the in vivo and/or ex vivo biodistribution of a compound and generate the relative time–activity curves.
• Import time–activity curve data into specialised dosimetry software to calculate organ- and tissue-specific absorbed doses, residence times, cumulated activities, and predict estimated patient dose.
• Use of OLINDA/EXM – The gold standard for internal dosimetry, used for regulatory submissions and patient dose estimation.
• Data analysis and interpretation performed by qualified medical physicists.